MedTrace Logo

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma

NCT01225315 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 438

Last updated 2018-07-09

No results posted yet for this study

Summary

This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only.

Conditions

Interventions

DRUG

Placebo

Matching placebo administered orally twice daily

DRUG

Setipiprant

ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Sara Mangialaio, MD · Actelion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-01
Primary Completion
2012-01-01
Completion
2012-02-01

Countries

  • United States
  • Australia
  • Bulgaria
  • Germany
  • Hungary
  • Israel
  • Poland
  • Russia
  • Serbia
  • Singapore
  • South Africa
  • Sweden
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01225315 on ClinicalTrials.gov